Chen Xiaoyu, Chen Peng
Department of Thoracic Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Zhongguo Fei Ai Za Zhi. 2024 Oct 20;27(10):755-762. doi: 10.3779/j.issn.1009-3419.2024.106.27.
At present, the incidence and mortality rates of lung cancer rank top among malignant tumors. The early diagnosis, treatment and drug resistance of lung cancer still remain as problems in the management of lung cancer. Researchers are dedicated to identifying reliable biomarkers as predictive indicators or effective therapeutic targets for lung cancer. Insulin resistance (IR), a disorder characterized by reduced biological activity of insulin, leads to increased insulin secretion. In recent years, more and more studies have revealed the association between IR and the occurrence and development of cancer, with the insulin/insulin-like growth factor signaling pathway possibly playing a crucial role. In this article, we will focus on the relationship between IR and lung cancer, explore the impact and mechanism of IR on the development, progression and drug resistance of lung cancer. It may guide the development of new predictive tools and therapeutic strategies, and provide new ideas for research dedicated to reducing the incidence and mortality of lung cancer. .
目前，肺癌的发病率和死亡率在恶性肿瘤中位居前列。肺癌的早期诊断、治疗以及耐药性仍是肺癌管理中的难题。研究人员致力于寻找可靠的生物标志物作为肺癌的预测指标或有效的治疗靶点。胰岛素抵抗（IR）是一种以胰岛素生物活性降低为特征的病症，会导致胰岛素分泌增加。近年来，越来越多的研究揭示了IR与癌症发生发展之间的关联，胰岛素/胰岛素样生长因子信号通路可能起着关键作用。在本文中，我们将聚焦于IR与肺癌之间的关系，探讨IR对肺癌发生、发展及耐药性的影响和机制。这可能会指导新的预测工具和治疗策略的开发，并为致力于降低肺癌发病率和死亡率的研究提供新思路。
